These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25481761)

  • 21. Nationwide survey of the development of drug resistance in the pediatric field in 2000-2001, 2004, 2007, 2010, and 2012: evaluation of the changes in drug sensitivity of Haemophilus influenzae and patients' background factors.
    Shiro H; Sato Y; Toyonaga Y; Hanaki H; Sunakawa K
    J Infect Chemother; 2015 Apr; 21(4):247-56. PubMed ID: 25596977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
    Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanism of macrolide-lincosamide resistance in Moraxella catarrhalis.
    Saito R; Nonaka S; Nishiyama H; Okamura N
    J Med Microbiol; 2012 Oct; 61(Pt 10):1435-1438. PubMed ID: 22820696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
    Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of next generation sequence to investigate potential novel macrolide resistance mechanisms in a population of Moraxella catarrhalis isolates.
    Liu YL; Li DF; Xu HP; Xiao M; Cheng JW; Zhang L; Xu ZP; Chen XX; Zhang G; Kudinha T; Kong F; Gong YP; Wang XY; Zhang YX; Wu HL; Xu YC
    Sci Rep; 2016 Oct; 6():35711. PubMed ID: 27774989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species.
    Higa F; Akamine M; Haranaga S; Tohyama M; Shinzato T; Tateyama M; Koide M; Saito A; Fujita J
    J Antimicrob Chemother; 2005 Dec; 56(6):1053-7. PubMed ID: 16260445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use.
    Cizman M; Beović B; Seme K; Paragi M; Strumbelj I; Müller-Premru M; Cad-Pecar S; Pokorn M
    Int J Antimicrob Agents; 2006 Dec; 28(6):537-42. PubMed ID: 17101264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moraxella (Branhamella) catarrhalis--clinical and molecular aspects of a rediscovered pathogen.
    Enright MC; McKenzie H
    J Med Microbiol; 1997 May; 46(5):360-71. PubMed ID: 9152030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moraxella catarrhalis as a respiratory pathogen.
    Gupta N; Arora S; Kundra S
    Indian J Pathol Microbiol; 2011; 54(4):769-71. PubMed ID: 22234107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A; Sader H; Jones RN;
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
    Mendes C; Kiffer CR; Blosser-Middleton RS; Jones ME; Karlowsky JA; Barth A; Rossi F; Andrade S; Sader HS; Thornsberry C; Sahm DF;
    Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. bro {beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults.
    Khan MA; Northwood JB; Levy F; Verhaegh SJ; Farrell DJ; Van Belkum A; Hays JP
    J Antimicrob Chemother; 2010 Jan; 65(1):91-7. PubMed ID: 19889789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility and mechanisms of high-level macrolide resistance in clinical isolates of Moraxella nonliquefaciens.
    Nonaka S; Matsuzaki K; Kazama T; Nishiyama H; Ida Y; Koyano S; Sonobe K; Okamura N; Saito R
    J Med Microbiol; 2014 Feb; 63(Pt 2):242-247. PubMed ID: 24196134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011.
    Kasai A; Ogihara S; Yamada K; Tanimichi Y; Nishiyama H; Saito R
    J Med Microbiol; 2015 Jul; 64(7):708-713. PubMed ID: 25934551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multilocus sequence typing-based analysis of Moraxella catarrhalis population structure reveals clonal spreading of drug-resistant strains isolated from childhood pneumonia.
    Du Y; Zhou H; Wang F; Liang S; Cheng L; Du X; Pang F; Tian J; Zhao J; Kan B; Xu J; Li J; Zhang F
    Infect Genet Evol; 2017 Dec; 56():117-124. PubMed ID: 29155241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of five quinolones, three macrolides and telithromycin against 12 Haemophilus influenzae strains with different resistance phenotypes.
    Pankuch GA; Lin G; Appelbaum PC
    Clin Microbiol Infect; 2005 Dec; 11(12):1040-4. PubMed ID: 16307562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.